Evaluation of clinical benefit from treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis

BACKGROUND: In a recent phase III trial (NCT02020889), 53% of mepolizumab-treated, versus 19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved protocol-defined remission. OBJECTIVE: To investigate post hoc the clinical benefit of mepolizumab in patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Allergy Clin Immunol
Main Authors: Steinfeld, Jonathan, Bradford, Eric S., Brown, Judith, Mallett, Stephen, Yancey, Steven W., Akuthota, Praveen, Cid, Maria C., Gleich, Gerald J., Jayne, David, Khoury, Paneez, Langford, Carol A, Merkel, Peter A., Moosig, Frank, Specks, Ulrich, Weller, Peter F., Wechsler, Michael E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7254609/
https://ncbi.nlm.nih.gov/pubmed/30578883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2018.11.041
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados